Similar articles

• The high cost of cancer drugs and what we can do about it.

  Rosamond T. Rosamond T. Mayo Clin Proc. 2013 Mar;88(3):306. doi: 10.1016/j.mayocp.2013.01.003. Epub 2013 Feb 27. Mayo Clin Proc. 2013. PMID: 23489458 No abstract available.
• Integrating value assessment into discussions about the price of cancer drugs.

  Bunnell C. Bunnell C. Mayo Clin Proc. 2012 Oct;87(10):932-4. doi: 10.1016/j.mayocp.2012.08.009. Mayo Clin Proc. 2012. PMID: 23036668 Free PMC article. No abstract available.
• The high cost of cancer drugs and what we can do about it.

  Siddiqui M, Rajkumar SV. Siddiqui M, et al. Mayo Clin Proc. 2012 Oct;87(10):935-43. doi: 10.1016/j.mayocp.2012.07.007. Mayo Clin Proc. 2012. PMID: 23036669 Free PMC article. No abstract available.
• Clinical research in metastatic prostate cancer: a focus on impact and value.

  Hussain M, DiPaola RS. Hussain M, et al. Am Soc Clin Oncol Educ Book. 2015:17-21. doi: 10.14694/EdBook_AM.2015.35.17. Am Soc Clin Oncol Educ Book. 2015. PMID: 25993136 Review. No abstract available.
• [Pharmacoeconomics and cost of cancer drugs].

  Camps Herrero C, Caballero Díaz C, Blasco Cordellat A. Camps Herrero C, et al. Farm Hosp. 2010 Mar;34 Suppl 1:12-5. doi: 10.1016/S1130-6343(10)70003-9. Farm Hosp. 2010. PMID: 20920852 Review. Spanish.